Extended Half-life Factor Products in the Management of Hemophilia

Slides:

Advertisements

Similar presentations

© 2014 Direct One Communications, Inc. All rights reserved. 1 Treatment of Hemophilia: What’s in the Pipeline? Kerry Hege, MD Indiana University School.

Advertisements

© 2014 Direct One Communications, Inc. All rights reserved. 1 Expanding Therapeutic Options for Hemophilia A and B: Results of Recent Clinical Trials Holleh.

Hemophilia Management: Joint Bleeds and Prophylaxis.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.

Specialty pharmacy Market overview

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Sites of Action in Coagulation System Novel Factor Xa and DT Inhibitors.

Engaging the INSULIN-TREATED T2DM Patient: the Importance of Real-World Data.

Advances in Managing Inhibitors in Patients With Hemophilia A

Prophylaxis Considerations for Teenagers and Young Adults With Severe Hemophilia.

Thrombosis, Cancer, and NOACs

Updates in Hodgkin Lymphoma

New Therapies for Hyperkalemia Across the Continuum of Care

Glaucoma Progression.

Cholesteryl Ester Transfer Protein Inhibitors

Metastatic Renal Cell Carcinoma

PCP Perspectives Clinical Considerations in Hyperkalemia

Hemophilia Updates: Incorporating New Concepts Into Practice

Extended Half-life Factor Products in the Management of Hemophilia

Managing Hereditary Angioedema

PARP and Other DNA Damage Repair Inhibitors in Solid Tumors: An Update

Individualizing Prophylaxis in Hemophilia

Hot Topics in Hemophilia Nursing

Mid-Year Hemophilia Update

Issues in the Management of Hemophilia: A Best Practice Series

Blood pressure control: dependence on adherence

Tailoring Hemophilia Prophylaxis Therapy

The Nurse View.

Clinical Updates in RA: New Developments and Insights From Washington

The future of urate-lowering strategies for gout

Addressing Challenges in Factor VIII Inhibitors in Children With Hemophilia.

Individualizing Factor Replacement Therapy for Patients With Hemophilia.

Program Goals. Single vs Dual HER2 Blockade for Metastatic HER2-Positive Breast Cancer.

Initiating Pre-exposure Prophylaxis The PrEP Checklist

Evaluating Next-Generation BTK Inhibitors

EHL Technologies in Hemophilia Care

Issues in the Management of Hemophilia: A Best Practice Series

Exploring Personalized Prophylaxis in Hemophilia A

Program Goals Overview Glatiramer Acetate 3 Times a Week.

Immunotherapy for cSCC

Personalized Therapy in Relapsed or Refractory CLL

LEADER One Year On.

DOACs and Urgent Bleeding

When Is Biologic Therapy Appropriate for HS?

NOACs in AF: Consequences of Underdosing and NonAdherence

Program Goals. Technological Advances in Longer-Acting Factor Replacement Therapy for Hemophilia.

Multidisciplinary Approaches to Managing Hemophilia

What Does It Take to Be a Long-Acting Replacement Therapy in Hemophilia A?

Novel Insulin/GLP-1 Combinations: Of Interest to the Primary Care Physician?

Prolonging the Effects of Factor IX Replacement Therapy in Hemophilia B.

IgG-Fc Fusion Proteins and Immunomodulation: What Does the Science Tell Us?

Updates From the 2015 Meetings in Hemophilia

Current Challenges in Managing Hemophilia

The Changing Field of Melanoma: Ipilimumab.

Optimizing Joint Health in Hemophilia

A Nursing Perspective on Improving Outcomes for Patients With Hemophilia.

Etiology and Incidence Pathophysiology Hemophilia is due to a defect in thrombin generation on the platelet surface.

NOACs in AF: Consequences of Underdosing and NonAdherence

HAVEN 2 Updated Analysis: Multicenter, Open-Label, Phase 3 Study to Evaluate Efficacy, Safety and Pharmacokinetics of Subcutaneous Administration of Emicizumab.

Essential Updates for PsA: A Complex Disease to Manage

Treating Atypical Hemolytic Uremic Syndrome A Case Discussion

Selecting Treatment Approaches in Hemophilia

Would Patients With Hemophilia B Benefit From Switching to Extended Half-Life Factor Products?

Real-World Evidence.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Real-World Data in Cardiology: Focus on Atrial Fibrillation

Identifying TRK Fusions in Head and Neck Cancer

Examining the Role of Pharmacokinetics in Hemophilia

Understanding the Expanding Armamentarium for GIST

Fresh perspectives ON BASAL Insulins in diabetes care

Presentation transcript:

Extended Half-life Factor Products in the Management of Hemophilia

Program Goal

Overview of New Factor Concentrates

Updates on Fc Fusion Protein Approach in Hemophilia A and B

Real-world Data With Recombinant Factor VIII Fc Fusion Protein

Investigational EHLs: Phase 3 Results

Other Novel Products

Patient Education

Identifying Candidates for EHLs

Pharmacokinetic Studies

Practice Issues

Adherence

Inhibitors

Prophylaxis Dosing

Summary

Abbreviations

References

References (cont)

References (cont)

References (cont)